John Morell Frellsen appointed CCO of DanCann Pharma A/S as from April 1, 2021 to accelerate the Company’s European penetration
COPENHAGEN, Denmark, 31 March 2021 - DanCann Pharma A/S (SS: DANCAN) (“DanCann Pharma” or the “Company”) a biopharmaceutical company powered by cannabinoids today announced that John M. Frellsen has been officially appointed as Chief Commercial Officer. John M. Frellsen has been acting as interim Chief Commercial Officer for the last six months and will continue as permanent Chief Commercial Officer at DanCann Pharma. John M. Frellsen’s employment with DanCann Pharma will commence in the beginning of April.John M. Frellsen is an experienced executive with a demonstrated successful history